

# ALPIC 2018

Advanced Learning on Platelets  
& Thrombosis International Course

**23-25 /** March 2018

Diasselo Conference Center

**METSOVO - GREECE**

## Course Directors

Alexandros Tselepis

Professor of Biochemistry-Clinical  
Chemistry Department of Chemistry,  
University of Ioannina

John Goudevenos

Professor of Cardiology,  
School of Medicine,  
University of Ioannina

## Organizer:



European and Mediterranean League  
Against Thrombotic Diseases

## Under the auspices of:



University  
of Ioannina



Hellenic  
Cardiological Society



Atherothrombosis  
Research Centre,  
University of Ioannina



Institute for the Study  
and Education on Thrombosis  
and Antithrombotic Therapy

## Endorsed by:



International Society on Thrombosis and Haemostasis

[www.alpic2018.gr](http://www.alpic2018.gr)

**Final Programme**


# *Eliquis*<sup>®</sup> apixaban

PP-ELI-GRC-0037-OCT16



**PFIZER HELLAS A.E.** Λεωφ. Μεσογείων 243, 154 51 Ν. Ψυχικό,  
Τηλ.: Επιστημονικής Ενημέρωσης: 210 67 85 800, Παραγγελιών: 210 81 99 060

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



# trinomia

acetylsalicylic acid • atorvastatin • ramipril

Κάθε καψάκιο περιέχει:

100mg ακετυλοσαλικυλικό οξύ

20mg ατορβαστατίνη

2.5 ή 5 ή 10mg ραμιπρίλη

TRINOMIX 2

 **Galenica a.e.**

Αθήνα: Ελευθερίας 4, Κηφισιά 145 64, τηλ.: 210 5281700  
Θεσσαλονίκη: Κουντουριώτου & Φασιανού 2, τηλ.: 2310 542685  
Επιστημονικό Τμήμα τηλ.: 210 5281731  
Τμήμα Φαρμακοεπαγρύπνησης τηλ.: 210 5281805  
[www.galenica.gr](http://www.galenica.gr)

**ΣΥΜΠΕΡΙΛΑΜΒΑΝΕΤΑΙ  
στο Θετικό Κατάλογο  
Συνταγογραφούμενων  
Φαρμάκων**

## TABLE OF CONTENTS

<b>Welcome Message .....</b>	<b>5</b>
<b>ALPIC Organizers &amp; Committees .....</b>	<b>6-7</b>
<b>General Information .....</b>	<b>8-10</b>
- Date & Venue/Educational Objectives/Official Languages Name Badge -Scanning/ .....	8
- Accreditation/Certificate of Attendance/Website PPT Presentations/Mobile Phones .....	9
- Liability and Insurance/Contact .....	10
<b>Scientific Programme .....</b>	<b>11-20</b>
- Friday, March 23 <sup>rd</sup> 2018 .....	11-14
- Saturday March 24 <sup>th</sup> 2018 .....	15-19
- Sunday March 25 <sup>th</sup> 2018 .....	22
<b>Index/ Invited Faculty .....</b>	<b>23-24</b>
<b>Satellite Symposia/Lectures .....</b>	<b>25</b>
<b>Sponsors .....</b>	<b>26</b>

## WELCOME MESSAGE

We are pleased to welcome you to ALPIC 2018 (Advanced Learning on Platelets & Thrombosis International Course), the seventh international scientific event on Platelets and Thrombosis, taking place this year at “Diasselo” Conference Center, in Epirus, Greece from March 23<sup>th</sup> to March 25<sup>th</sup> 2018.

Since its inception in 2010, ALPIC has played a major role as a knowledge transfer forum for scientists in the current aspects of Platelet and Thrombosis research, ranging from the basic science to the clinical practice.

This year ALPIC is guided by EMLTD foundation and we are proud that it has gain worldwide warm acceptance and recognition for its scientific merit.

We do hope that this year ALPIC will strengthen the European and Mediterranean network for Thrombosis research and we do believe that a jointly organized programme with the contribution of our hosting partners, the Atherothrombosis Research Centre (ARC) of the University of Ioannina and the Institute for the Study and Education on Thrombosis and Antithrombotic Therapy (ISETAT), would become beneficial for all of us and it would be an opportunity to bring together even more scientists and experts who will share current knowledge on various aspects of Thrombosis.

An internationally recognized panel of invited speakers will present state of-the-art lectures and will create an excellent opportunity for all participants to stimulate an extended and very constructive discussion both inside and outside the lecture hall. The Organizers will spare no effort to ensure that ALPIC 2018 will be an exciting and enriching experience. Looking forward to welcoming you and we wish you all enjoy ALPIC 2018 in the picturesque landscape offered by Metsovo and its mountainous landscape.

With our best regards,

The President of the EMLTD Foundation  
**Professor Lina Badimon**

ALPIC 2018 Course Directors  
**Professor John Goudevenos      Professor Alexandros Tselepis**

## ALPIC ORGANIZERS & COMMITTEES

### ■ Organizer:

---



European and Mediterranean League Against Thrombotic Diseases

### ■ Under the auspices of:

---



University of Ioannina



Hellenic Cardiological Society



Atherothrombosis Research Centre,  
University of Ioannina



Institute for the Study  
and Education on Thrombosis  
and Antithrombotic Therapy

### ■ Endorsed by:

---



International Society on Thrombosis and Haemostasis

### ■ Course Directors:

---

#### **Alexandros Tselepis**

Professor of Biochemistry-Clinical  
Chemistry, Department of Chemistry,  
University of Ioannina,  
Ioannina, Greece

#### **John Goudevenos**

Professor of Cardiology,  
Faculty of Medicine,  
School of Health Sciences.  
University of Ioannina,  
Ioannina, Greece

## ALPIC ORGANIZERS &amp; COMMITTEES

## Local Scientific Committee

Alexopoulos Dimitrios	Kanonidis Ioannis	Papadopoulos Thomas
Andrikopoulos George	Karvounis Haralambos	Pappas Christos
Arnaoutoglou Eleni	Katsouras Christos	Pappas Konstantinos
Bakas Thomas	Kohiadakis George	Parthenakis Fragkiskos
Bampali Theodora	Konstantinides Stavros	Pattakos Gregory
Bissas Apostolos	Korantzopoulos Panagiotis	Petrou Anastasios
Boumpas Alexios	Koroboki Eleni	Pipilis Athanasios
Chalikias George	Kotsia Anna	Richter Dimitrios
Chantanis Stylianos	Koutsias Stylianos	Skoularigis John
Davlouros Periklis	Koutsilieris Michalis	Sourmelis Savas
Fousas Stefanos	Lefkou Elmina	Stratou Athina
Giannakoulas George	Letsas Konstantinos	Tselegidi Maria-Irini
Giannoukas Athanasios	Makos Xenofon	Tselepis Alexandros
Godevenos Dimitrios	Margaritis Athanasios	Tsiara Stavroula
Goudevenos John	Matsagkas Miltiadis	Tsolakis John
Goumas George	Michalis Lampros	Tsoukatos Demokritos
Hahalis George	Milionis Haralampos	Tzimas Petros
Hatzimichael Eleftheria	Mitsiadis Sotirios	Vavouranakis Emmanouil
Iliodromitis Efstathios	Naka Katerina	Vemmos Konstantinos
Iliopoulos Dimitrios	Nikas Dimitrios	Vlachopoulos Haralampos
Kalantzi Kallirroï	Ntaios Georgios	Voudris Vasileios
Kanakakis John	Ntarladimas Ioannis	Zacharoulis Achilles

## International Scientific Advisory Board

Badimon Lina (Spain)	Michelson Alan (USA)
Brillakis Manos (USA)	Morrow David (USA)
Cattaneo Marco (Italy)	Padró Teresa (Spain)
Douketis James (Canada)	Paganelli Franck (France)
Elalamy Ismail (France)	Papageorgiou Chrysoula (France)
Falanga Anna (Italy)	Papanagiotou Panagiotis (Germany)
Gerotziafas Grigoris (France)	Papavasileiou Vasileios (UK)
Gilles Montalescot (France)	Patrono Carlo (Italy)
Gurbel Paul (USA)	Price Matthew (USA)
Heptinstall Stan (UK)	Schaefer Katrin (Germany)
Larsen Annette (France)	Spyropoulos Alex (USA)
Mallett Susan (UK)	



## GENERAL INFORMATION

**DATE & VENUE**

ALPIC 2018 Course, is held from **Friday, March 23<sup>th</sup> to Sunday, March 25<sup>th</sup> 2018** in Metsovo, at **"Diasselo" Conference Center**, Epirus, Greece. The Course commences with Registration on Friday, March 23<sup>th</sup> in the morning, and concludes on Sunday, March 25<sup>th</sup> 2018 at noon.

**EDUCATIONAL OBJECTIVES**

This educational course aims to promote and co-ordinate a critical and open discussion on several topics of Platelet and trombosis research, ranging from basic science to the clinical practice, thus providing the attendees with a comprehensive overview on the established knowledge and ongoing evolution on Platelet pathophysiology and pharmacology. Participants will attend an intensive training programme focused on the role of Platelets in atherogenesis and cardiovascular disease as well as on the recent advances in antiplatelet and antithrombotic therapy. At the conclusion of the course participants should be able to discuss on several aspects of Platelets and Trombosis covered by the course and to integrate into their research projects and/or clinical practice the knowledge obtained through discussion with experts and review questions.

**LANGUAGES**

The official languages of the course are **Greek** and **English**. The English language may be used widely especially in the presentations of the speakers to encourage the interaction in all scientific sessions of the English speaking faculty.

**NAME BADGE-SCANNING**

All participants, upon confirmation of their registration at the Secretariat, will be provided with a name badge that bears a unique barcode.

It must be clearly understood that barcode badges must be scanned **before entering AND after exiting the Lecture Hall**.

**According to the National Organization of Medicines Regulation participation for at least of 60% of the total duration of the scientific programme must be secured and recorded!**



## GENERAL INFORMATION

### **Notes:**

- It is obligatory - for all participants to wear their badges always during the Congress.
- Barcode name badge already appointed for recording attendance cannot be replaced with a second badge.
- Name badges are also necessary for admittance to the social events.
- Please be returned to the Secretariat for receiving the Certificate of Attendance.
- Time slots for breaks will not be recorded.

### **CERTIFICATE OF ATTENDANCE**

All registered participants are entitled to receive a Certificate of Attendance. The Certificate will be issued on Sunday, March 25th 2018 at the end of the Scientific Programme and only upon return of the name badge and the completed Evaluation Form at the Secretariat desk.

### **WEBSITE**

The official course website <http://www.alpic2018.gr> & <http://www.medleague-thrombosis.org> will provide the participants with a wide range of information. Participants are kindly requested to visit the site regularly for all updates.

### **PPT PRESENTATIONS**

All who have presentations are kindly requested to deliver their presentation(s) in PPT format to the technical support personnel at least one (1) hour before the beginning of the Session (in order to ensure on time they run smoothly and to be able of making any possible changes). If the presentation is scheduled early in the morning, you are kindly requested to check your presentation with the technical support personnel the day before.

### **MOBILE PHONES**

Everyone is requested to switch off his/her mobile phone while in session Halls.

## GENERAL INFORMATION

---

**■ LIABILITY AND INSURANCE**

---

The Organizers as well as the Organizing-Administrative Bureau will assume no liability for injuries or losses of any nature incurred by participants and/or accompanying persons, or for the damage, loss or theft of their personal property during the Congress. Participants are advised to take out their own health, travel and personal insurances.

---

**■ CONTACT**

---

Organizing-Administrative Bureau/Secretariat:

**Conferre S.A.**

Stavrou Niarchou Avenue, Mares Position, Pedini

GR 45500 Ioannina, Greece

Tel.: (+30) 26510 68610, Fax: (+30) 26510 68611

E-mail: [info@conferre.gr](mailto:info@conferre.gr), Website: [www.conferre.gr](http://www.conferre.gr)

Friday, March 23<sup>rd</sup>, 2018**09.00-11.00 Multispecialty strategies to improve perioperative management of anticoagulant and antiplatelet therapy**Moderators: **John Goudevenos, John Kanakakis****Topics to be presented as a series of case studies:**

Venous thromboprophylaxis of medically ill patients, when antithrombotic interruption is not needed, to continue aspirin or not, how to bridge, to continue DOAC around minor procedures

Discussants:

**Dimitrios Godevenos, Apostolos Bissas,  
Athanasios Margaritis, Sotirios Mitsiadis, Alexios Boumpas,  
Konstantinos Pappas, Maria-Irini Tselegidi**

**11.00-11.30 Coffee Break****11.30-13.00 Clinical trials and top publications of antithrombotic therapy in 2017 - 2018**Chairmen: **George Hahalis, Efstathios Iliodromitis**

Presentation of the recent important trials and publications

**Trials**

Re-Dual  
Compass  
COMPASS-CAT  
BRUISE CONTROL-2  
DACAM  
Hokusai VTE Cancer  
My Take Away ACC 2018  
EPCAT II

**Presenters**

**Anna Kotsia  
Athanasios Pipilis  
Grigorios Gerotziafas  
Xenofon Makos  
Athina Stratou  
Eleftheria Hatzimichael  
Dimitrios Alexopoulos  
John Goudevenos**

**Friday, March 23<sup>rd</sup>, 2018**

### **13.00-14.30 Clinical seminar: Management challenges of antithrombotics**

Moderators: **Emmanouil Vavouranakis, Stylianos Chantanis**

Presentation of complex cases dealing with venous/arterial thrombosis discussed by a panel of experts

Discussants:

**Athanasios Giannoukas, John Kanakakis,  
Miltiadis Matsagkas, John Skoularigis, Dimitrios Iliopoulos**

### **14.30-15.00 Lecture**

Chairman: **John Skoularigis**

Heart failure with or without AF. Choosing the right anticoagulant  
**Katerina Naka**

### **15.00-17.30 Break**

### **17.30-18.00 Official opening of ALPIC 2018**

Vice Rector of the University of Ioannina  
**Thomas Bakas**

President of EMLTD  
**Lina Badimon** (Spain)

President of ISETAT  
**George Andrikopoulos**

Councilor of the ISTH Board Council  
**Anna Falanga** (Italy)

President-Elect of the Hellenic Cardiological Society  
**John Goudevenos**

## SCIENTIFIC PROGRAMME

**Friday, March 23<sup>rd</sup>, 2018**

### **18.00-19.00 Distinguished lectures**

Chairmen: **Alexandros Tselepis, Haralambos Karvounis**

New data on perioperative laboratory testing for DOAC patients who have major surgery

**Jim Douketis** (USA)

Precision Medicine. Antithrombotic therapy in PAD

**Miltiadis Matsagkas**

### **19.00-19.30 Lecture**

Chairman: **Stefanos Fousas**

The PAD landscape after COMPASS trial

**Haralampos Vlachopoulos**

### **19.30-20.00 Sponsored lecture**

See page 25

## SCIENTIFIC PROGRAMME

Friday, March 23<sup>rd</sup>, 2018**20.00-21.00 Round Table: When bleeding occurs**Chairmen: **George Kohiadakis, Christos Katsouras**

Defining the high risk bleeding patients

**Kallirroï Kalantzi**Expert Consensus: Management of Bleeding in Patients  
on DOACs**George Andrikopoulos**

Specific Reversal Agents

**Alexandros Tselepis**

Laboratory parameters in urgent DOAC Reversal

**Elmina Lefkou****21.00****Dinner**

**Saturday, March 24<sup>th</sup>, 2018**

### **08.30-10.30 Clinical Workshop: The Gap between Guidelines and reality**

Moderators: **John Goudevenos, Dimitrios Richter**

Topics to be presented as a series of case studies

AF ablation, PFO, left atrial appendage occlusion, TAVI, CKB, how much AF is too much AF, CAD and AF with cancer, AF post-CABG

Discussants:

**Emmanouil Vavouranakis, Panagiotis Korantzopoulos, George Goumas, Gregory Pattakos, Konstantinos Letsas, Konstantinos Pappas, Dimitrios Nikas**

---

### **10.30-11.00 Coffee Break**

### **11.00-12.15 Distinguished lectures**

Chairmen: **Lampros Michalis, Vasileios Voudris**

Mechanisms and risk factors of thrombosis in cancer

**Anna Falanga** (Italy)

New paradigms in risk assessment and thromboprophylaxis in medical and surgical patients

**Alex Spyropoulos** (USA)

Anticoagulants and Antiplatelet Agents: Future Allies in the Era of Thrombocardiology?

**Stavros Konstantinides**

---



**Saturday, March 24<sup>th</sup>, 2018****12.15-13.30 Precision Medicine. Antithrombotic therapy in ACS**

Moderators: **Dimitrios Alexopoulos, Periklis Davlourous**

Preload, Switching, DAPT duration, Triple therapy (when and which antiplatelet agent should be dropped), IIb/IIIa inhibitors, Bivalirudin, Heparin

Discussants:

**Ioannis Ntarladimas, Thomas Papadopoulos,  
Athanasios Pipilis, Achilles Zacharoulis, Christos Pappas**

**13.30-14.00 Sponsored lecture**

See page 25

**14.00-16.00 Lunch Break**

Saturday, March 24<sup>th</sup>, 2018**16.00-18.00 Meet the Experts: Perioperative Management of Antithrombotics**

Chairmen: **Jim Douketis** (Canada), **Alex Spyropoulos** (USA)

**Short Introduction:** Managing DOAC patients who need an elective or urgent surgery

**Eleni Arnaoutoglou**

**Case 1:** DOAC patient has elective surgery (e.g., lap colectomy) and then comes back 2 weeks later with complication (e.g., perforation) and now requires emergency surgery

**Petros Tzimas**

**Short Introduction:** Perioperative management of VKA- and DOAC-treated patients who are having a cardiac device procedure

**Theodora Bampali**

**Case 2:** Patient on a VKA or DOAC who needs a cardiac procedure (pacemaker, ICD, catheter ablation); Need to reverse? When to stop/resume VKA/DOAC?

**Dimitrios Richter**

**Short Introduction:** Perioperative management of patients on DAPT who need surgery

**Emmanouil Vavouranakis**

**Case 3:** Patient on DAPT who needs elective or urgent surgery: How to reverse antiplatelet drugs? Role of bridging (cangrelor)?

**Periklis Davlourous**

**Short Introduction:** Perioperative thromboprophylaxis in high-risk patients

**Anastasios Petrou**

**Case 4:** Patient having elective major orthopedic or cancer surgery: Which agent to prevent VTE? Duration of prophylaxis?

**Savas Sourmelis**

## SCIENTIFIC PROGRAMME

**Saturday, March 24<sup>th</sup>, 2018****18.00-18.30 Distinguished lecture**

Chairman: **Michalis Koutsilieris**

Future therapeutic strategies for atherothrombosis

**Lina Badimon** (Spain)

**18.30-19.30 Round Table: New Antithrombotic Strategies in Cancer Patients**

Chairmen: **Anna Falanga** (Italy), **Grigorios Gerotziafas** (France)

The vascular tumor microenvironment: new challenges and therapeutic targets

**Annette Larsen** (France)

A modern concept for Cancer Associated Prevention in ambulatory patients with solid tumors

**Grigorios Gerotziafas** (France)

LMWH or DOAC in Cancer Associated Thrombosis?

**Eleftheria Hatzimichael**

**19.30-20.00 Lecture**

Chairman: **Fragkiskos Parthenakis**

Edoxaban-Betrixaban. Do we really need novel DOACs?

**Alexandros Tselepis**

**Saturday, March 24<sup>th</sup>, 2018**

**20.00-21.00 Meet the experts: Management of Venous thromboembolism (VTE)**

Chairmen: **John Tsolakis, Ioannis Kanonidis**

Optimal Duration of Anticoagulation After VTE

**George Giannakoulas**

Extended thromboprophylaxis in medically ill patients

**Stavroula Tsiara**

Prevention of DVT in Orthopaedic procedures

**Savas Sourmelis**

New aspects on the management of Pulmonary Embolism Risk

**George Chalikias**

Discussant: **Stylianos Koutsias**

---

**Sunday, March 25<sup>th</sup>, 2018****09.00-11.00 Round table. Building a Multidisciplinary Team for Interventional Acute Stroke Management**

Chairmen: **Konstantinos Vemmos, Haralampos Milionis**

Who should perform acute stroke intervention and what training is needed?

**Konstantinos Vemmos**

A practical guide to intravenous thrombolysis

**Georgios Ntaios**

Acute stroke intervention: Does it parallel to primary PCI for acute MI?

**Dimitrios Nikas**

Patient selection for acute stroke intervention

**Vasileios Papavasileiou** (UK)

Endovascular thrombectomy in acute ischemic stroke

**Panagiotis Papanagiotou** (Germany)

Antithrombotic strategy after intracranial hemorrhage

**Eleni Koroboki**

Sunday, March 25<sup>th</sup>, 2018**11.00-12.00 Round table: Recent advances in thrombosis research**Chairmen: **Demokritos Tsoukatos, Vasileios Voudris**

Short Oral Presentations from submitted abstracts

**Molecular Hybrids of natural products bearing enhanced and triple antiplatelet activity**Antonis Tsailanis<sup>1</sup>, Evgenios Stylos<sup>1,2</sup>, Kostantinos Tellis<sup>3</sup>, Maria Tsoumani<sup>3</sup>, Maria Chatziathanassiadou<sup>1</sup>, Alexandros D. Tselepis<sup>3</sup>, Andreas G. Tzakos<sup>1</sup><sup>1</sup>Laboratory of Organic Chemistry, Department of Chemistry,<sup>2</sup>Laboratory of Biotechnology, Department of Biological Applications and Technologies, <sup>3</sup>Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece**Activated platelets induce NETosis and neutrophil migration: The effect of antiplatelet drugs**Iraklis C. Moschonas<sup>1</sup>, Styliani Papadaki<sup>1</sup>, Konstantinos Kambas<sup>2</sup>, Dimitrios Stakos<sup>3</sup>, Konstantinos Ritis<sup>2</sup>, Alexandros D. Tselepis<sup>1</sup><sup>1</sup>Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece,<sup>2</sup>Laboratory of Molecular Hematology, and <sup>3</sup>Cardiology Department, Democritus University of Thrace, Alexandroupolis, Greece**Vorapaxar inhibits the interaction of CD34<sup>+</sup> progenitor cells with platelets**Styliani Papadaki, Iraklis C. Moschonas, Alexandros D. Tselepis  
Atherothrombosis Research Centre/Laboratory of Biochemistry,  
Department of Chemistry, University of Ioannina, Greece

Sunday, March 25<sup>th</sup>, 2018

### **Acute Stent Thrombosis and Heparin Induced Thrombocytopenia in a Patient with Acute Coronary Syndrome**

V. Voudris MD<sup>1</sup>, P. Georgiadou MD<sup>1</sup>, P. Kalogris MD<sup>2</sup>,  
S. Dimopoulos MD<sup>3</sup>, T. Kostelidou MD<sup>4</sup>, G. Gerotziakas MD<sup>5</sup>,  
A. Karabinis MD<sup>3</sup>

<sup>1</sup>Division of Interventional Cardiology, <sup>2</sup>Division of Cardiothoracic Surgery, <sup>3</sup>Division of Intensive Care Unit, <sup>4</sup>Division of Thrombosis and Hemostasis, <sup>5</sup>Service D Hematologie Biologique

### **Low dose ticagrelor versus low dose prasugrel in patients with prior myocardial infarction**

Ioannis Lianos<sup>1</sup>, Danai Sfantou<sup>2</sup>, Christos Pappas<sup>3</sup>,  
Dimitrios Alexopoulos<sup>4</sup>

<sup>1,3,4</sup>Second Department of Cardiology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, <sup>2</sup>Department of Internal Medicine, Elpis Hospital of Athens, Greece

### **The effect of imatinib and its synthetic analogues on platelet activation**

Despoina Pantazi<sup>1</sup>, Nikoleta Demou<sup>2</sup>, Konstantinos Skobridis<sup>2</sup>,  
Alexandros D. Tselepis<sup>1</sup>

<sup>1</sup>Atherothrombosis Research Centre/Laboratory of Biochemistry and <sup>2</sup>Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece

### **The role of the antiplatelet agent vorapaxar on platelet-mediated inflammation**

Aikaterini N. Tsouka, Iraklis C. Moschonas, Styliani Papadaki,  
Alexandros D. Tselepis

Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece



## INDEX/ INVITED FACULTY

<b>A</b>		Goumas George	15
Alexopoulos Dimitrios	11, 16	<b>H</b>	
Andrikopoulos George	12, 14	Hahalis George	11
Arnaoutoglou Eleni	17	Hatzimichael Eleftheria	11, 18
<b>B</b>		<b>I</b>	
Badimon Lina	12, 18	Iliodromitis Efstathios	11
Bakas Thomas	12	Iliopoulos Dimitrios	12
Bampali Theodora	17	<b>K</b>	
Bissas Apostolos	11	Kalantzi Kallirroi	14
Boumpas Alexios	11	Kanakakis John	11, 12
<b>C</b>		Kanonidis Ioannis	19
Chalikias George	19	Karvounis Haralambos	13
Chantanis Stylianos	12	Katsouras Christos	14
<b>D</b>		Kohiadakis George	14
Davlouros Periklis	16, 17	Konstantinides Stavros	15
Douketis Jim	13, 17	Korantzopoulos Panagiotis	15
<b>F</b>		Koroboki Eleni	20
Falanga Anna	12, 15, 18	Kotsia Anna	11
Fousas Stefanos	13	Koutsias Stylianos	19
<b>G</b>		Koutsilieris Michalis	18
Gerotziakas Grigorios	11, 18	<b>L</b>	
Giannakoulas George	19	Larsen Annette	18
Giannoukas Athanasios	12	Lefkou Elmina	14
Godevenos Dimitrios	11	Letsas Konstantinos	15
Goudevenos John	11, 12, 13, 15		

## INDEX/ INVITED FACULTY

## M

Makos Xenofon	11
Margaritis Athanasios	11
Matsagkas Miltiadis	12, 13
Michalis Lampros	15
Milionis Haralampos	20
Mitsiadis Sotirios	11

## N

Naka Katerina	12
Nikas Dimitrios	13, 15, 16, 20
Ntaios Georgios	20
Ntarladimas Ioannis	16

## P

Papadopoulos Thomas	16
Papanagiotou Panagiotis	20
Papavasileiou Vasileios	20
Pappas Christos	16
Pappas Konstantinos	11, 15
Parthenakis Fragkiskos	18
Pattakos Gregory	15
Petrou Anastasios	17
Pipilis Athanasios	11, 16

## R

Richter Dimitrios	15, 17
-------------------	--------

## S

Skoularigis John	12
Sourmelis Savas	17, 19
Spyropoulos Alex	15, 17
Stratou Athina	11

## T

Tselegidi Maria-Irini	11
Tselepis Alexandros	13, 14, 18
Tsiara Stavroula	19
Tsolakis John	19
Tsoukatos Demokritos	20
Tzimas Petros	17

## V

Vavouranakis Emmanouil	12, 15, 17
Vemmos Konstantinos	20
Vlachopoulos Haralampos	13
Voudris Vasileios	15, 21

## Z

Zacharoulis Achilles	16
----------------------	----

## SATELLITE SYMPOSIA/LECTURES

**Friday, March 23<sup>rd</sup>, 2018**

**19.30-20.00 Sponsored lecture**

**AMGEN**

Chairman: **John Goudevenos**

PCSK9 inhibition: The role of evolocumab in managing cardiovascular risk

**Dimitrios Nikas**

---

**Saturday, March 24<sup>th</sup>, 2018**

**13.30-14.00 Sponsored lecture**

**AstraZeneca**

Oral antiplatelet therapy in Acute Coronary Syndromes without persistent ST-segment elevation (NSTEMI-ACS): From theory to clinical practice

**Dimitrios Nikas**

---

## SPONSORS

The Organizers wish to thank the following pharmaceutical and / or equipment / device companies for their support in the accomplishment of the course:

### Major Sponsors



Bayer &



ESSENTIAL HEALTH

### Sponsors



Boehringer  
Ingelheim



Galenica a.e.



Pharmaceutical Laboratories S.A.

1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ PLATOREL 5 mg επικαλυμμένα με λεπτό υμένιο δισκία. PLATOREL 10 mg επικαλυμμένα με λεπτό υμένιο δισκία. PLATOREL 20 mg επικαλυμμένα με λεπτό υμένιο δισκία. PLATOREL 40 mg επικαλυμμένα με λεπτό υμένιο δισκία. 2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ Κάθε 5 mg δισκίο περιλαμβάνει 5 mg ροσουβαστατίνης ισοδύναμης με 5,2 ροσουβαστατίνης ασβεστιούχου. Επίσης περιέχει 48,2 mg lactose monohydrate. Κάθε 10 mg δισκίο περιέχει 10 mg ροσουβαστατίνης ισοδύναμης με 10,4 ροσουβαστατίνης ασβεστιούχου. Επίσης περιέχει 96,4 mg lactose monohydrate. Κάθε 20 mg δισκίο περιέχει 20 mg ροσουβαστατίνης ισοδύναμης με 20,8 ροσουβαστατίνης ασβεστιούχου. Επίσης περιέχει 192,8 mg lactose monohydrate. Κάθε 40 mg δισκίο περιέχει 40 mg ροσουβαστατίνης ισοδύναμης με 41,7 ροσουβαστατίνης ασβεστιούχου. Επίσης περιέχει 171,9 mg lactose monohydrate. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1 της Περιλήψης Χαρακτηριστικών του Προϊόντος (ΠΧΠ).

Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.



PLA/FPA/01-2018/03



# PLATOREL®


## Ροσουβαστατίνη



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ  
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,  
Τηλ.: 210 6039326-9, Fax: 210 6039300  
[www.elpen.gr](http://www.elpen.gr)

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ  
Σεβαστείας 11, 115 28 Αθήνα,  
Τηλ.: 210 7488711, Fax: 210 7488731  
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,  
Τηλ.: 2310 459920-1, Fax: 2310 459269

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



# Xarelto®

rivaroxaban



L.GR.MKT.GM.10.2016.0599



## Bayer

Κάτοχος της άδειας κυκλοφορίας:  
Bayer Pharma AG, 13342 Berlin, Γερμανία  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς ABEE,  
Σωρού 18-20, 151 25 Μαρούσι,  
Τοπικός αντιπρόσωπος του κατόχου άδειας  
κυκλοφορίας στην Κύπρο: Novagem Ltd,  
Τηλ:00357 22483858

Τμήμα Επιστημονικής Ενημέρωσης  
Τηλ: +30 210 6187742, Fax: +30 210 6187522  
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπτρώθησης  
για τα 15 & 20mg



**ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ**  
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,  
Τηλ: 210 6039326 - 9, Fax: 210 6039300  
**ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ**  
Σεβαστείας 11, 115 28 Αθήνα,  
Τηλ: 210 7488711, Fax: 210 7488731  
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,  
Τηλ: 2310 459920 - 1, Fax: 2310 459269

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Πριν τη συνταγογράφηση για κάθε ένδειξη συμβουλευθείτε την αντίστοιχη Περίληψη των Χαρακτηριστικών του Προϊόντος.